TRDA Entrada Therapeutics, Inc.
$6.80▲ +5.92%
Healthcare
Other
After hours
$6.48▼ -4.71%
Sep 11, 7:30 PM ET
Volume 291.8K
Avg Volume (10D) 344.7K
Key Metrics & Fundamentals
Market Cap
$264.77M
P/E Ratio
–
Div Yield
–%
52W Range
5.02 - 16.45
% vs 50 MA
-3.05%
% vs 200 MA
-29.36%
RSI-14
45.6
MACD Histogram
-0.0800
Beta (1Y vs SPY)
1.51
Free Cash Flow
-$32.47M
Gross Rev
$898,000
Gross Profit
$898,000
EBITDA
-$44.12M
COGS
–
Operating Exp
$45.86M
Operating Income
-$44.96M
EBIT
-$44.96M
Pretax Income
-$42.73M
Net Income
-$42.76M
EPS (Diluted)
-1.01
Price & Volume History
Loading chart…
Recent News
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
GlobeNewswire · Sep 10, 2026 11:00 AM
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 8:30 PM
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 5, 2026 1:00 PM
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 5, 2026 11:00 AM
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
MT Newswires · Aug 3, 2026 9:33 PM
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 3, 2026 12:05 PM
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Jul 30, 2026 1:35 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See TRDA's money flow as a full page
Social Sentiment
No Reddit posts found for TRDA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.